Latest News and Press Releases

Meaningful Fatigue score reduction seen in study is a critically important quality of life (QoL) measure for Multiple Sclerosis patients.All patients experienced stabilization of Expanded Disability...

SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Researchers at the University of Alabama at Birmingham (UAB) have identified what is believed to be the first intervention found in a randomized...

SAN FRANCISCO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Researchers at New York University (NYU) found that a particular set of brain exercises lowered the incidence of the all-too-common symptom of...

The first patient has been dosed in Tisento's global Phase 2b PRIZM study investigating zagociguat in MELAS.

Cheyenne, WY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- EarthFlow LLC is excited to announce the launch of its new grounding website. The website offers a variety of premier products at cost-effective...

- IMC-2 treatment, dosed as valacyclovir 750 mg + celecoxib 200 mg twice daily, demonstrated clinically meaningful reduction in Long-COVID related fatigue and sleep disturbance as compared to placebo...

- Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) formed in October by combination of Virios Therapeutics, Inc. and Pharmagesic (Holdings) Inc., 100% parent company of Wex Pharmaceuticals, Inc. (the...

Strategic financing by an affiliate of CK Life Sciences Int’l., (Holdings) Inc., results in working capital of approximately $23 million to fund operations and advance Phase 2b Halneuron® development...

- Virios projects releasing top line results from this groundbreaking Proof of Concept study in October 2024 - - Published data indicates increased Epstein-Barr herpes virus in Long-COVID patients,...

- Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring valacyclovir and celecoxib (IMC-2) expected in the second-half of 2024 - - Conference Call...